European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men Developed by the Guideline Subcommittee “Androgenetic Alopecia” of the European Dermatology Forum

European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men Developed by the Guideline Subcommittee “Androgenetic Alopecia” of the European Dermatology Forum European Dermatology Forum – 2017.

European Dermatology Forum (EDF) presenta una completa guía en la que se describe la etiología, fisiopatología y epidemiología de la alopecia androgénica. El documento brinda recomendaciones para el diagnóstico y lineamientos pormenorizados sobre las diferentes opciones terapéuticas.

ABSTRACT
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.